INVO Fertility ( (IVF) ) has released a notification of late filing.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
INVO Fertility, Inc. has filed a Form 12b-25 to notify investors of a delay in submitting its Form 10-K (Yearly Report) for the fiscal year ended December 31, 2025. The company’s annual filing will cover the full-year 2025 results and is being pushed beyond the original SEC deadline.
Management cites the need for additional time to finalize its financial statements as the main reason for the delay. In particular, INVO Fertility is still reviewing certain tax-related matters, suggesting the issue is technical rather than tied to broader operational disruptions.
The company states that it expects to file the Form 10-K (Yearly Report) within the standard 15-calendar-day extension window allowed under SEC rules. Investors should therefore anticipate the annual report to be submitted shortly after the original due date, assuming no further complications arise.
INVO Fertility has also warned that it anticipates a significant change in results of operations for 2025 compared with 2024, but it has not yet provided either narrative detail or quantitative guidance. Because the tax review and financials are not finalized, the company says it cannot reasonably estimate the magnitude or direction of those changes, making all such comments forward-looking and subject to revision.
The company affirms that all other required periodic filings over the past 12 months have been submitted on time, signaling ongoing baseline compliance with SEC obligations. The notification was signed on April 1, 2026, by Chief Executive Officer Steve Shum, underscoring senior management’s responsibility for the delayed Form 10-K (Yearly Report) and its commitment to complete the filing within the permitted extension period.
The most recent analyst rating on (IVF) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on INVO Fertility stock, see the IVF Stock Forecast page.
Spark’s Take on IVF Stock
According to Spark, TipRanks’ AI Analyst, IVF is a Neutral.
The score is primarily held back by weak financial performance (persistent losses, declining gross margin, and negative operating/free cash flow). Technicals are only mildly supportive, while valuation lacks support due to negative earnings and no dividend data. Corporate events are mixed—growth initiatives and financing help, but dilution risk and the reverse split temper the upside.
To see Spark’s full report on IVF stock, click here.
More about INVO Fertility
Average Trading Volume: 1,440,093
Technical Sentiment Signal: Strong Sell
Current Market Cap: $4.39M
For an in-depth examination of IVF stock, go to TipRanks’ Overview page.